Related Experiment Video
Updated: Jul 6, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
[Clinical evaluation and immunomodulatory study of cefodizime]
Insights
Cefodizime demonstrates efficacy and safety in treating infections in immunocompromised patients. This antibiotic also shows beneficial immunomodulating activities, unlike ceftizoxime.
Area of Science:
- Infectious Diseases
- Immunology
- Pharmacology
Background:
- Immunocompromised patients are susceptible to various infections.
- Assessing novel antibiotic treatments and their immunomodulatory effects is crucial.
Purpose of the Study:
- To evaluate the efficacy, safety, and immunomodulating potential of cefodizime.
- To compare cefodizime with ceftizoxime in immunocompromised patients.
Main Methods:
- A randomized controlled prospective study involving 107 patients.
- Comparison of cefodizime and ceftizoxime treatment groups.
- Assessment of clinical cure rates, bacterial eradication, and immune function parameters.
Main Results:
- Cefodizime showed effective cure (87.3%) and bacterial eradication (61.8%) rates.
- Cefodizime enhanced phagocyte and lymphocyte functions, including CD4+ counts and NK cell activity.
- Ceftizoxime did not exhibit similar immunomodulatory effects.
Conclusions:
- Cefodizime is effective and safe for treating lower respiratory tract infections (LRTI) and urinary tract infections (UTI) in immunocompromised individuals.
- Cefodizime possesses significant immunomodulating properties, offering potential advantages over ceftizoxime.
Abstract:
To investigate the efficacy, safety and immunomodulating activities of cefodizime in immunocompromised patients with infections, we carried out a randomized controlled prospective study of cefodizime vs ceftizoxime in 107 patients. The total effective cure rate and bacterial eradication rate were 87.3%, 61.8% and 89.3% in cefodizime group and 82.7%, 59.6% and 90.6% in ceftizoxime group. Drug tolerance was similar in the two groups, and side effect was mild and transient, mainly gastrointestinal reactions. Cefodizime had effect on both phagocyte and lymphocyte functions: enhancing the phagocytie rate, phagocytic index and bacterial killing activity, increasing the number of CD4+ lymphacyte and the ratio of CD4+/CD8+, stimulating NK cell activity and enhancing expression of IL-2R of active lymphocyte. Meanwhile ceftizoxime had no effect on any of the parameter mentioned above. The result showed that cefodizime is effective and safe in the treatment of LRTI, upper and complicated UTI in immunocompromised patients, as well as possessed immunomodulating activities.
More Related Videos
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Antimicrobial Effectiveness
Microbiota Modulation by Antibiotics

